Aspira Womens Health (Aspira Womens Health) Earnings per Share (Diluted) : $-1.76 (TTM As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Aspira Womens Health Earnings per Share (Diluted)?

Aspira Womens Health's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.27. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.76.

Aspira Womens Health's EPS (Basic) for the three months ended in Dec. 2023 was $-0.27. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.76.

Aspira Womens Health's EPS without NRI for the three months ended in Dec. 2023 was $-0.45. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.93.

During the past 3 years, the average EPS without NRIGrowth Rate was 9.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was -2.10% per year. During the past 10 years, the average EPS without NRI Growth Rate was 9.20% per year.

During the past 13 years, Aspira Womens Health's highest 3-Year average EPS without NRI Growth Rate was 39.10% per year. The lowest was -21.20% per year. And the median was 19.30% per year.

Aspira Womens Health Earnings per Share (Diluted) Historical Data

The historical data trend for Aspira Womens Health's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aspira Womens Health Earnings per Share (Diluted) Chart

Aspira Womens Health Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Earnings per Share (Diluted)

Get a 7-Day Free Trial

-2.70

-4.27

-3.85

-1.81

Aspira Womens Health Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Earnings per Share (Diluted)	Get a 7-Day Free Trial															-0.60	-0.73	-0.28	-0.48	-0.27

Competitive Comparison of Aspira Womens Health's Earnings per Share (Diluted)

For the Diagnostics & Research subindustry, Aspira Womens Health's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aspira Womens Health's PE Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Aspira Womens Health's PE Ratio distribution charts can be found below:

* The bar in red indicates where Aspira Womens Health's PE Ratio falls into.

Aspira Womens Health Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Aspira Womens Health's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-16.69	-	0)	/	9.233
	=	-1.81

Aspira Womens Health's Earnings Per Share (Diluted) for the quarter that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends	/	Shares Outstanding (Diluted Average)
	=	(-3.089	-	0)	/	10.418
	=	-0.30

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.76

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.

Aspira Womens Health (NAS:AWH) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Aspira Womens Health Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Aspira Womens Health's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Aspira Womens Health (Aspira Womens Health) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Aspira Womens Health Inc (NAS:AWH) » Definitions » Earnings per Share (Diluted)

Comparable Companies

Traded in Other Exchanges

N/A

Address

12117 Bee Caves Road, Suite 100, Building 3, Austin, TX, USA, 78738

Website

https://www.aspirawh.com

Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. The Company markets and sells, 1) Ova1, a blood test intended as an aid to assess the likelihood of malignancy in women with an ovarian adnexal mass for which surgery is planned when the physician's independent clinical and radiological evaluation does not indicate malignancy; (2) Overa, a second-generation biomarker reflex intended to maintain Ova1's high sensitivity while improving specificity; (3) Ova1Plus, a reflex offering which uses Ova1 as the primary test and Overa as a confirmation for Ova1 intermediate range results; and (4) OvaWatch, a lab-developed blood test intended to assist in the initial clinical assessment of malignancy risk in all women with an adnexal mass.

Executives

Nicole Sandford	director	12117 BEE CAVES RD BLDG 3, STE 100, AUSTIN TX 78738
Minh Hoang Merchant	officer: General Counsel & Secretary	1210 AVONDALE ROAD, HILLSBOROUGH CA 94010
Torsten Hombeck	officer: Chief Financial Officer	529 W 42ND ST #6V, NEW YORK NY 10036
Celeste Rachelle Fralick	director	2801 MESA ROAD, LUBBOCK TX 79403
Veronica Gh Jordan	director	C/O ALBANY MOLECULAR RESEARCH, INC., 26 CORPORATE CIRCLE, ALBANY NY 12212-5098
Stefanie L. Cavanaugh	director	1120 S CAPITAL OF TX HWY, BLDG 1, STE 300, AUSTIN TX 78746
Ellen O'connor Vos	director	C/O NTELOS HOLDINGS CORP., 1154 SHENANDOAH VILLAGE DRIVE, WAYNESBORO VA 22980
Jack W Schuler	10 percent owner	100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Ryan Thinh Phan	officer: CSO & COO	327 CARLTON AVE, LOS GATOS CA 95032
Jannie Prestridge Herchuk	director	6331 LAVENDALE AVE, DALLAS TX 75230
Winfred Parnell	director	6734 TALMADGE LANE, DALLAS TX 75230
Marlene Mclennan	officer: Interim Chief Financial Office	400 SOUTH AUSTRALIAN AVENUE, SUITE 800, WEST PALM BEACH FL 33401
Ruby Sharma	director	24 ARNOLD DRIVE, PRINCETON JCT. NJ 08550
Robert D Auerbach	director	C/O THE COOPER COMPANIES, INC., SUITE 590, PLEASANTON CA 94588
Valerie Barber Palmieri	director, officer: President and CEO	63 INDIAN LEDGE RD., MONROE CT 06468